Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2025-02-14 06:46 am Sale | 2024-12-31 | 13G | Ocular Therapeutix, Inc. OCUL | Opaleye Management Inc. | 4,342,500 2.760% | -1,727,500 (-28.46%) | Filing History |
| 2025-02-14 06:42 am Purchase | 2024-12-31 | 13G | iBio, Inc. IBIO | Opaleye Management Inc. | 750,000 7.600% | 100,000 (+15.38%) | Filing History |
| 2025-02-14 06:31 am Purchase | 2024-12-31 | 13G | Protara Therapeutics, Inc. TARA | Opaleye Management Inc. | 1,825,000 5.320% | 143,846 (+8.56%) | Filing History |
| 2025-02-14 06:27 am Sale | 2024-12-31 | 13G | Context Therapeutics Inc. CNTX | Opaleye Management Inc. | 0 0.000% | -820,000 (Position Closed) | Filing History |
| 2024-11-18 06:01 am Purchase | 2024-09-30 | 13G | Protara Therapeutics, Inc. TARA | Opaleye Management Inc. | 1,681,154 8.150% | 1,681,154 (New Position) | Filing History |
| 2024-10-22 7:44 pm Purchase | 2024-10-18 | 13G | SANUWAVE Health, Inc. SNWV | Opaleye Management Inc. | 944,132 11.060% | 944,132 (New Position) | Filing History |
| 2024-09-18 4:50 pm Purchase | 2024-09-17 | 13G | Codexis, Inc. CDXS | Opaleye Management Inc. | 7,524,000 10.610% | 3,984,000 (+112.54%) | Filing History |
| 2024-09-12 4:05 pm Purchase | 2024-09-09 | 13G | Eton Pharmaceuticals, Inc. ETON | Opaleye Management Inc. | 2,722,500 10.340% | 197,613 (+7.83%) | Filing History |
| 2024-07-12 4:15 pm Purchase | 2024-07-03 | 13G | Codexis, Inc. CDXS | Opaleye Management Inc. | 3,540,000 5.020% | 3,540,000 (New Position) | Filing History |
| 2024-04-09 5:22 pm Unchanged | 2024-03-28 | 13G | iBio, Inc. IBIO | Opaleye Management Inc. | 650,000 7.630% | 0 (Unchanged) | Filing History |
| 2024-04-08 8:18 pm Purchase | 2024-03-28 | 13G | iBio, Inc. IBIO | Opaleye Management Inc. | 650,000 7.630% | 650,000 (New Position) | Filing History |
| 2024-02-14 7:48 pm Sale | 2023-12-31 | 13G | Ocular Therapeutix, Inc. OCUL | Opaleye Management Inc. | 6,070,000 5.510% | -5,000 (-0.08%) | Filing History |
| 2024-02-14 4:05 pm Purchase | 2023-12-31 | 13G | SANUWAVE Health, Inc. SNWV | Opaleye Management Inc. | 307,983 9.090% | 224,173 (+267.48%) | Filing History |
| 2024-02-09 4:05 pm Sale | 2023-12-31 | 13G | Jounce Therapeutics, Inc. JNCE | Opaleye Management Inc. | 0 0.000% | -2,810,000 (Position Closed) | Filing History |
| 2024-02-09 4:05 pm Purchase | 2023-12-31 | 13G | Harrow Health, Inc. HROW | Opaleye Management Inc. | 3,820,000 10.880% | 45,000 (+1.19%) | Filing History |
| 2024-02-09 4:05 pm Sale | 2023-12-31 | 13D | TRACON Pharmaceuticals, Inc. TCON | Opaleye Management Inc. | 0 0.000% | -125,919 (Position Closed) | Filing History |
| 2024-02-09 4:05 pm Purchase | 2023-12-31 | 13G | Eton Pharmaceuticals, Inc. ETON | Opaleye Management Inc. | 2,524,887 9.840% | 354,887 (+16.35%) | Filing History |
| 2024-01-05 4:05 pm Purchase | 2023-12-27 | 13G | Context Therapeutics Inc. CNTX | Opaleye Management Inc. | 820,000 5.140% | 820,000 (New Position) | Filing History |
| 2023-04-12 4:15 pm Purchase | 2022-03-30 | 13G | Jounce Therapeutics, Inc. JNCE | Opaleye Management Inc. | 2,810,000 5.390% | 2,810,000 (New Position) | Filing History |
| 2023-02-13 4:05 pm Sale | 2022-12-30 | 13G | Chimerix, Inc. CMRX | Opaleye Management Inc. | 0 0.000% | -5,580,000 (Position Closed) | Filing History |